Colin M Court1,2,3, Jacob S Ankeny1,2, Shonan Sho1,2, Paul Winograd1,2, Shuang Hou1,4, Min Song4, Zev A Wainberg5, Mark D Girgis1, Thomas G Graeber3,4, Vatche G Agopian1, Hsian-Rong Tseng4, James S Tomlinson6,7,8. 1. Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. 2. Department of Surgery, Veteran's Health Administration, Los Angeles, CA, USA. 3. Department of Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, CA, USA. 4. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. 5. Department of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA. 6. Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. jtomlinson@mednet.ucla.edu. 7. Department of Surgery, Veteran's Health Administration, Los Angeles, CA, USA. jtomlinson@mednet.ucla.edu. 8. California NanoSystems Institute (CNSI), University of California Los Angeles, Los Angeles, CA, USA. jtomlinson@mednet.ucla.edu.
Abstract
BACKGROUND: Occult metastatic tumors, below imaging thresholds, are a limitation of staging systems that rely on cross-sectional imaging alone and are a cause of the routine understaging of pancreatic ductal adenocarcinomas (PDACs). We investigated circulating tumor cells (CTCs) as a preoperative predictor of occult metastatic disease and as a prognostic biomarker for PDAC patients. EXPERIMENTAL DESIGN: A total of 126 patients (100 with cancer, 26 with benign disease) were enrolled in our study and CTCs were identified and enumerated from 4 mL of venous blood using the microfluidic NanoVelcro assay. CTC enumeration was correlated with clinicopathologic variables and outcomes following both surgical and systemic therapies. RESULTS: CTCs were identified in 78% of PDAC patients and CTC counts correlated with increasing stage (ρ = 0.42, p < 0.001). Of the 53 patients taken for potentially curative surgery, 13 (24.5%) had occult metastatic disease intraoperatively. Patients with occult disease had significantly more CTCs than patients with local disease only (median 7 vs. 1 CTC, p < 0.0001). At a cut-off of three or more CTCs/4 mL, CTCs correctly identified patients with occult metastatic disease preoperatively (area under the receiver operating characteristic curve 0.82, 95% confidence interval (CI) 0.76-0.98, p < 0.0001). CTCs were a univariate predictor of recurrence-free survival following surgery [hazard ratio (HR) 2.36, 95% CI 1.17-4.78, p = 0.017], as well as an independent predictor of overall survival on multivariate analysis (HR 1.38, 95% CI 1.01-1.88, p = 0.040). CONCLUSIONS: CTCs show promise as a prognostic biomarker for PDAC patients at all stages of disease being treated both medically and surgically. Furthermore, CTCs demonstrate potential as a preoperative biomarker for identifying patients at high risk of occult metastatic disease.
BACKGROUND: Occult metastatic tumors, below imaging thresholds, are a limitation of staging systems that rely on cross-sectional imaging alone and are a cause of the routine understaging of pancreatic ductal adenocarcinomas (PDACs). We investigated circulating tumor cells (CTCs) as a preoperative predictor of occult metastatic disease and as a prognostic biomarker for PDACpatients. EXPERIMENTAL DESIGN: A total of 126 patients (100 with cancer, 26 with benign disease) were enrolled in our study and CTCs were identified and enumerated from 4 mL of venous blood using the microfluidic NanoVelcro assay. CTC enumeration was correlated with clinicopathologic variables and outcomes following both surgical and systemic therapies. RESULTS: CTCs were identified in 78% of PDACpatients and CTC counts correlated with increasing stage (ρ = 0.42, p < 0.001). Of the 53 patients taken for potentially curative surgery, 13 (24.5%) had occult metastatic disease intraoperatively. Patients with occult disease had significantly more CTCs than patients with local disease only (median 7 vs. 1 CTC, p < 0.0001). At a cut-off of three or more CTCs/4 mL, CTCs correctly identified patients with occult metastatic disease preoperatively (area under the receiver operating characteristic curve 0.82, 95% confidence interval (CI) 0.76-0.98, p < 0.0001). CTCs were a univariate predictor of recurrence-free survival following surgery [hazard ratio (HR) 2.36, 95% CI 1.17-4.78, p = 0.017], as well as an independent predictor of overall survival on multivariate analysis (HR 1.38, 95% CI 1.01-1.88, p = 0.040). CONCLUSIONS: CTCs show promise as a prognostic biomarker for PDACpatients at all stages of disease being treated both medically and surgically. Furthermore, CTCs demonstrate potential as a preoperative biomarker for identifying patients at high risk of occult metastatic disease.
Authors: Katrin Hoffmann; Christiane Kerner; Wolfgang Wilfert; Marc Mueller; Joachim Thiery; Johann Hauss; Helmut Witzigmann Journal: World J Gastroenterol Date: 2007-01-14 Impact factor: 5.742
Authors: Colin M Court; Jacob S Ankeny; Shuang Hou; Hsian-Rong Tseng; James S Tomlinson Journal: Expert Rev Mol Diagn Date: 2015-09-21 Impact factor: 5.225
Authors: Timothy R Donahue; William H Isacoff; O Joe Hines; James S Tomlinson; James J Farrell; Yasser M Bhat; Edward Garon; Barbara Clerkin; Howard A Reber Journal: Arch Surg Date: 2011-07
Authors: Ali A Mokdad; Rebecca M Minter; Hong Zhu; Mathew M Augustine; Matthew R Porembka; Sam C Wang; Adam C Yopp; John C Mansour; Michael A Choti; Patricio M Polanco Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff Journal: PLoS Med Date: 2010-04-20 Impact factor: 11.069
Authors: F C Bidard; F Huguet; C Louvet; L Mineur; O Bouché; B Chibaudel; P Artru; F Desseigne; J B Bachet; C Mathiot; J Y Pierga; P Hammel Journal: Ann Oncol Date: 2013-05-14 Impact factor: 32.976
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: L Khoja; A Backen; R Sloane; L Menasce; D Ryder; M Krebs; R Board; G Clack; A Hughes; F Blackhall; J W Valle; C Dive Journal: Br J Cancer Date: 2011-12-20 Impact factor: 7.640
Authors: Jan Budczies; Frederick Klauschen; Bruno V Sinn; Balázs Győrffy; Wolfgang D Schmitt; Silvia Darb-Esfahani; Carsten Denkert Journal: PLoS One Date: 2012-12-14 Impact factor: 3.240
Authors: Marian Liberko; Katarina Kolostova; Arpad Szabo; Robert Gurlich; Martin Oliverius; Renata Soumarova Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Na Sun; Yingying Yang; Hui Miao; Peter Redublo; Hongtao Liu; Wenfei Liu; Yen-Wen Huang; Pai-Chi Teng; Ceng Zhang; Ryan Y Zhang; Matthew Smalley; Peng Yang; Shih-Jie Chou; Kevin Huai; Zhicheng Zhang; Yi-Te Lee; Jasmine J Wang; Jing Wang; Icy Y Liang; Tiffany X Zhang; Dongyun Zhang; Li Liang; Paul S Weiss; Edwin M Posadas; Timothy Donahue; J Randolph Hecht; Martin S Allen-Auerbach; Emily K Bergsland; Thomas A Hope; Renjun Pei; Yazhen Zhu; Hsian-Rong Tseng; Anthony P Heaney Journal: Biosens Bioelectron Date: 2021-12-03 Impact factor: 12.545
Authors: Susanne Roth; Christoph Springfeld; Markus K Diener; Christine Tjaden; Phillip Knebel; Ulla Klaiber; Christoph W Michalski; Markus Mieth; Dirk Jäger; Markus W Büchler; Thilo Hackert Journal: BMJ Open Date: 2019-08-20 Impact factor: 2.692
Authors: Matthew S Dietz; Thomas L Sutton; Brett S Walker; Charles E Gast; Luai Zarour; Sidharth K Sengupta; John R Swain; Jennifer Eng; Michael Parappilly; Kristen Limbach; Ariana Sattler; Erik Burlingame; Yuki Chin; Austin Gower; Jose L Montoya Mira; Ajay Sapre; Yu-Jui Chiu; Daniel R Clayburgh; SuEllen J Pommier; Jeremy P Cetnar; Jared M Fischer; Jerry J Jaboin; Rodney F Pommier; Brett C Sheppard; V Liana Tsikitis; Alison H Skalet; Skye C Mayo; Charles D Lopez; Joe W Gray; Gordon B Mills; Zahi Mitri; Young Hwan Chang; Koei Chin; Melissa H Wong Journal: Sci Rep Date: 2021-07-01 Impact factor: 4.379